Lixisenatide

Green-G

Brand Name(s):Lyxumia

Indication:Diabetes – Type 2

Rationale:

Considered:Jan-13

Review Date:May-22

Comments:
NICE NG28 Update Type 2 diabetes in adults: management
May 2017
…………………………
NICE guidelines [NG18]
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Aug 2015
…………………………
Lixisenatide Guidance
Lixisenatide is to be initiated by a consultant endocrinologist, diabetic nurse specialist or general practitioner or nurse practitioner with special interest in diabetes.

The transfer time to hand over prescribing from Specialist care to Primary care will be 1 month, with a requirement that the patient will receive a specialist follow up at 6 months (maximum).